Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Three cancer-focused firms have launched. Tizona Therapeutics is emerging from stealth mode with more than $70 million to support the development of immunotherapies for cancer and autoimmune diseases. Tizona expects to put its first drug candidate, an antibody against CCR4, a protein expressed on certain T cells, into human studies in 2017. Separately, Horizon Discovery and Centauri Therapeutics have formed the immuno-oncology firm Avvinity Therapeutics. Horizon will contribute gene-editing, immunology, and drug discovery expertise and invest up to $7.5 million in Avvinity. Lastly, Capella BioScience launched with $15.5 million in funding to develop antibodies against cancer and immunology targets.
This article has been sent to the following recipient: